UP TO 400 patients a year are
likely to live longer as a result of
NZ’s PHARMAC funding two new
medicines, the organisation said.
Azacitidine (Vidaza) for blood
disorders collectively known as
myelodysplastic syndromes and two
types of leukaemia and lenalidomide
(Revlimid) for multiple myeloma will
be funded from 01 Sep.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.